milleflore-images-shutterstock-com
Milleflore Images / Shutterstock.com
21 April 2016AmericasShirley Liang

What Canada can learn from SPCs in Europe

To ensure for the public the safety and efficacy of drugs, such products are subjected to a rigorous and generally lengthy regulatory approval process before marketing authorisation (MA) is available. Furthermore, the extensive testing, including pre-clinical and clinical studies required to support a MA application may take a number of years.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 April 2026   The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.
Americas
29 April 2026   The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.
Americas
28 April 2026   Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug